Company intelligence / Profile preview

Metabiologics

Madison, Wisconsin, United States

Ownership: Private
Development stage: Other

Overview

Metabiologics is a globally recognized specialist in the production and distribution of research-grade botulinum neurotoxins for scientific and government use. Acquired by Object Pharma in 2019, it continues as a wholly owned subsidiary, supplying all seven serotypes of botulinum toxin to researchers and government agencies worldwide. Its products are used in drug development, biosecurity, and the manufacture of antibodies for toxin neutralization.

Therapeutic areas: Infectious DiseasesNeurology
Modalities: Protein
Industry: Non-Drug Biotech

Partnerships

Supplies to major pharmaceutical companies, U.S. government agencies (CDC, FDA, Army, Navy), and foreign governments (UK, Germany, France, Sweden) for research and biodefense

Beyond the preview

Go deeper on Metabiologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metabiologics.

Explore the full profile